Residency · Residency · Obstetrics Gynecology

Sexual Health and Female Sexual Dysfunction

Introduction

Female sexual dysfunction (FSD) affects approximately 40% of women at some point in their lives, yet remains underdiagnosed due to patient reluctance and provider discomfort. OB/GYN physicians are uniquely positioned to screen for, evaluate, and manage sexual health concerns. A biopsychosocial approach is essential, as sexual function is influenced by hormonal, vascular, neurologic, psychological, relational, and sociocultural factors.

Normal Female Sexual Response

The Basson circular model is the most clinically useful framework for female sexual response. It recognizes that women may begin from sexual neutrality, with responsive desire emerging from adequate stimulation in the context of emotional intimacy and psychological receptivity. This contrasts with the linear Masters and Johnson model. Key neurotransmitters include dopamine and norepinephrine (excitatory) and serotonin (primarily inhibitory). Estrogen maintains genital tissue health while testosterone contributes to desire through a complex, non-linear relationship.

Classification of Female Sexual Dysfunction

Female Sexual Interest/Arousal Disorder (FSIAD)

The DSM-5 combined desire and arousal into FSIAD, defined as reduced or absent sexual interest, fantasies, initiation, arousal, and pleasure persisting for at least 6 months with significant distress. The prevalence is 8-10% of women aged 18-44. Etiology is multifactorial: hormonal (menopause, hyperprolactinemia, hormonal contraception), medication-related (SSRIs, antihypertensives), psychological (depression, anxiety, trauma), relational, and sociocultural.

Female Orgasmic Disorder

This is defined as marked delay, infrequency, or absence of orgasm during virtually all sexual encounters. Primary (lifelong) anorgasmia suggests developmental or psychological etiology; secondary (acquired) warrants medical evaluation. Directed masturbation programs are the most effective treatment for primary anorgasmia.

Genito-Pelvic Pain/Penetration Disorder

This encompasses previously separate diagnoses of dyspareunia and vaginismus. Superficial (introital) causes include vulvovaginal atrophy, vulvar dermatoses, vulvodynia/vestibulodynia, and infections. Deep dyspareunia causes include endometriosis, adhesive disease, adenomyosis, and interstitial cystitis.

<image>Diagram illustrating the Basson circular model of female sexual response, showing the cycle from sexual neutrality through willingness to become receptive, subjective arousal, responsive desire, physical arousal, orgasm and satisfaction, with emotional intimacy and contextual factors influencing each transition</image>

Evaluation

Sexual History Taking

ACOG recommends incorporating sexual health into routine visits with a simple opening question such as "Are you satisfied with your sexual function?" The dysfunction is characterized by onset (lifelong versus acquired), context (generalized versus situational), temporal relationships, and degree of personal distress. Partner factors and relationship dynamics are assessed.

Physical Examination

Vulvar inspection assesses for atrophy, erythema, fissures, and skin changes. The cotton swab (Q-tip) test systematically palpates the vulvar vestibule to localize tenderness in vestibulodynia. Pelvic floor assessment evaluates levator ani tone, tenderness, and ability to contract and relax; hypertonicity suggests myofascial pain.

Laboratory Evaluation

Testing is not routinely required but may include thyroid function, prolactin, estradiol, and depression screening. SHBG may be elevated with oral contraceptives, reducing bioavailable testosterone.

Management

Non-Pharmacologic Interventions

Psychoeducation addresses sexual myths and anatomic education. CBT is evidence-based for desire, arousal, and orgasmic disorders. Mindfulness-based therapy reduces cognitive distraction and improves subjective arousal. Pelvic floor physical therapy is first-line for vaginismus, myofascial pain, and vestibulodynia with 70-80% success rates. Couples therapy is valuable when relational factors are prominent.

Pharmacologic Interventions

Flibanserin (Addyi), a 5-HT1A agonist/5-HT2A antagonist for premenopausal HSDD, provides modest efficacy (0.5-1 additional satisfying events per month) but is contraindicated with alcohol. Bremelanotide (Vyleesi), a melanocortin receptor agonist given subcutaneously before anticipated activity, causes nausea in 40%. Topical estrogen is first-line for GSM-related dyspareunia. Ospemifene is an oral SERM for moderate-severe vulvovaginal atrophy. Off-label transdermal testosterone (300 mcg/day) for postmenopausal HSDD shows modest benefit in systematic reviews, though no FDA-approved product exists for women. Intravaginal DHEA (prasterone/Intrarosa) improves dyspareunia from vulvovaginal atrophy.

<image>Anatomical illustration of the vulvar vestibule showing the locations tested during the cotton swab (Q-tip) test for provoked vestibulodynia, with numbered clock-face positions around the vestibule and the hymenal remnant, indicating typical areas of maximal tenderness at 5 and 7 o'clock positions</image>

Management of Specific Conditions

Vestibulodynia requires a multimodal approach: pelvic floor PT, topical lidocaine, topical estrogen/testosterone cream, amitriptyline or gabapentin; vestibulectomy is reserved for refractory cases with 70-90% success. SSRI-induced dysfunction may respond to dose reduction, switching to bupropion, or adding bupropion as adjunct. Postpartum sexual dysfunction is common and multifactorial, benefiting from reassurance, pelvic floor rehabilitation, and topical estrogen for lactation-related atrophy.

<image>Flowchart for the evaluation and management of female sexual dysfunction, beginning with screening questions, followed by characterization of the dysfunction type (desire, arousal, orgasm, pain), assessment for contributing factors (hormonal, psychological, relational, medical), and stepwise management from psychoeducation and behavioral therapy through pharmacologic interventions</image>

Clinical Pearls

Routinely screen for sexual health concerns at gynecologic visits -- most patients will not volunteer symptoms without being asked. The Basson circular model is more clinically relevant than linear models, as many women experience responsive rather than spontaneous desire. Pelvic floor physical therapy is first-line for genito-pelvic pain/penetration disorder. No FDA-approved testosterone product exists for women; off-label transdermal testosterone may be considered for postmenopausal HSDD after thorough counseling. Sexual dysfunction is almost always multifactorial -- a biopsychosocial evaluation and multimodal treatment plan yields the best outcomes.

References

1. Shifren JL, Monz BU, Russo PA, et al. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol. 2008;112(5):970-978.
2. Goldstein I, Kim NN, Clayton AH, et al. Hypoactive Sexual Desire Disorder: ISSWSH Expert Consensus Panel Review. Mayo Clin Proc. 2017;92(1):114-128.
3. Kingsberg SA, Clayton AH, Pfaus JG. The female sexual response: current models, neurobiological underpinnings, and agents currently approved or under investigation. CNS Drugs. 2015;29(11):915-933.
4. American College of Obstetricians and Gynecologists. Female sexual dysfunction. Practice Bulletin No. 213. Obstet Gynecol. 2019;134(1):e1-e18.

Read this lecture as Markdown